EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER

EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER

Show other versions (1)

Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization...

Full description

Bibliographic Details
Main Authors:	D. I. Ganov, S. A. Varlamov
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Onkourologiâ
Subjects:	castration refractory prostate cancer sustained-release octreotide
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/224

Similar Items

EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
by: D. I. Ganov, et al.
Published: (2014-07-01)

Experience with octreotide depot in the treatment of castration-resistant prostate cancer
by: G. P. Kolesnikov
Published: (2015-06-01)

THERAPY WITH SOMATOSTATIN ANALOGUES IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER
by: K. Y. Kanukoev, et al.
Published: (2015-04-01)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
by: Pascoe Abigail C, et al.
Published: (2012-03-01)

CURRENT POSSIBILITIES OF TREATMENT FOR VISCERAL METASTASES IN PATIENTS WITH METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. V. Govorov, et al.
Published: (2014-07-01)

CURRENT POSSIBILITIES OF TREATMENT FOR VISCERAL METASTASES IN PATIENTS WITH METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. V. Govorov, et al.
Published: (2014-07-01)

A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Study of the economic efficiency of the combined method of Octreotide-depo + dexamethasone therapy in the treatment of patients with castration-resistant prostate cancer
by: S. V. Mishugin, et al.
Published: (2019-06-01)

Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
by: Geehyun Song, et al.
Published: (2013-09-01)

THE ATYPICAL SITE OF URETERAL METASTASIS IN A PATIENT WITH CASTRATION-REFRACTORY PROSTATE CANCER. A CLINICAL CASE AND A REVIEW OF LITERATURE
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

THE ATYPICAL SITE OF URETERAL METASTASIS IN A PATIENT WITH CASTRATION-REFRACTORY PROSTATE CANCER. A CLINICAL CASE AND A REVIEW OF LITERATURE
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

BISPHOSPHONATES IN PROPHYLAXIS OF SKELETAL-RELATED ADVERSE EVENTS IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER
by: E. Yu. Safronova, et al.
Published: (2016-06-01)

Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
by: Minyong Kang, et al.
Published: (2015-12-01)

Diferelin® as an effective chemical castration agent for patients with prostate cancer
by: K. M. Nyushko, et al.
Published: (2021-02-01)

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
by: Magdalena Schrank, et al.
Published: (2020-01-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

A fluorescence-based assay for octreotide in kinetic release from depot formulations
by: Luiz Henrique Guerreiro, et al.
Published: (2012-01-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

Drug treatment opportunities of the elderly patients with the metastatic castration-resistant prostate cancer
by: V. A. Solodkiy, et al.
Published: (2017-04-01)

A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
by: Chadi Nabhan, et al.
Published: (2011-07-01)

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
by: Caffo O, et al.
Published: (2016-12-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
by: Sanjoy Kumar Sureka, et al.
Published: (2016-01-01)

ROLE OF DEGARELIX (FIRMAGON) IN THE TREATMENT OF DISSEMINATED PROSTATE CANCER: CAN THE QUALITY OF CASTRATION THERAPY BE IMPROVED?
by: V. B. Matveev, et al.
Published: (2014-07-01)

ROLE OF DEGARELIX (FIRMAGON) IN THE TREATMENT OF DISSEMINATED PROSTATE CANCER: CAN THE QUALITY OF CASTRATION THERAPY BE IMPROVED?
by: V. B. Matveev, et al.
Published: (2014-07-01)

HORMONE THERAPY WITH USAGE OF AGONISTS AND ANTAGONISTS OF LUTEINIZING HORMONE RELEASING HORMONE IN PATIENTS WITH PROSTATE CANCER
by: K. M. Nyushko, et al.
Published: (2015-01-01)

Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer
by: Fabrizio Fontana, et al.
Published: (2021-05-01)

The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
by: Tony Wu, et al.
Published: (2016-12-01)

Update in palliative management of hormone refractory cancer of prostate
by: Pratipal Singh, et al.
Published: (2007-01-01)

The first experience in using abiraterone acetate in patients with castration-refractory prostate cancer
by: L. M. Rapoport, et al.
Published: (2015-11-01)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
by: Yuki Kita, et al.
Published: (2018-09-01)

Darolutamide For Castration-Resistant Prostate Cancer
by: Bastos DA, et al.
Published: (2019-10-01)

Pathogenesis of prostate cancer and hormone refractory prostate cancer
by: J S Girling, et al.
Published: (2007-01-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies
by: K. M. Nyushko, et al.
Published: (2014-12-01)